Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer
Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer
复制标题
DOI：
10.1002/ijc.10145
复制
发表时间：
2002-03-01
影响因子：
6.4
通讯作者：
Itoh, K
中科院分区：
文献类型：
--
作者：
Suzuki, N;Maeda, Y;Itoh, K
胰腺癌的预后极差，5年生存率约为3%。因此，需要开发新的治疗方式，包括特异性免疫疗法。我们的研究调查了细胞毒性t淋巴细胞（CTL）前体是否在15例胰腺癌患者接种前外周血单个核细胞（PBMCs）中检测到与候选疫苗（分别为HLA-A2（+）或-A24（+）患者的13条肽）反应的肽。大多数患者（15.73%）检测到肽特异性CTL前体，平均每个患者检测到1.5个肽（范围从0-5个肽）。阳性肽谱因患者而异。这些结果可能为胰腺癌患者CTL前体导向肽疫苗的新型肿瘤免疫治疗提供科学依据。(C) 2002 Wiley-Liss, Inc。
The prognosis of pancreatic cancer is extremely poor with a 5-year survival of approximately 3%. Thus, the development of new treatment modalities, including a specific immunotherapy, is required. Our study investigated whether cytotoxic T-lymphocyte (CTL) precursors reacting to peptides with vaccine candidates (13 peptides for HLA-A2(+) or -A24(+) patients, respectively) were detectable in the prevaccination peripheral blood mononuclear cells (PBMCs) of 15 pancreatic cancer patients. Peptide-specific CTL precursors were detectable in the majority (I I of 15, 73%) of patients, with a mean positive number of 1.5 peptides (ranging from 0-5 peptides) per patient. Positive peptide profiles varied among patients. These results may provide a scientific basis for a new kind of cancer immunotherapy, namely, a CTL precursor-oriented peptide vaccine, for pancreatic cancer patients. (C) 2002 Wiley-Liss, Inc.